

Treatment Appraisal: Decision Summary

Date	12 th April 2011			
Appraisal	Bevacizumab (Avastin®) for neovascular glaucoma secondary to ischaemic central retinal vein occlusion			
Details	The North East Treatment Advisory Group considered the use of bevacizumab (Avastin®) outside of its product license in the management of neovascular glaucoma secondary to ischaemic CRVO			
Recommendation	<p>Bevacizumab (Avastin®) is not recommended for use within NHS North East for the treatment of neovascular glaucoma.</p> <p>The group recognised that there may be a particular patient group who could benefit from treatment but that the current evidence base was not adequate to support wider use.</p> <p>Individual patients in exceptional circumstances may be suitable for treatment. Such cases must be referred via local individual funding request mechanisms.</p>			
Clinical evidence summary	There is a large volume of evidence for bevacizumab in neovascular glaucoma however it is generally of low quality and it is difficult to identify the specific benefit, if any, of using bevacizumab. No new or unexpected safety issues arose from use of bevacizumab in neovascular glaucoma.			
Cost analysis summary	Bevacizumab is estimated to cost about £120 per pre-filled syringe, with admission costing about £600 and a mean of 1.1 admissions per episode. Mean cost per patient per episode is estimated at about £800.			
Financial impact		Estimated number of patients per annum	Estimated cost of bevacizumab	Estimated cost with admission
	NHS Durham & Darlington	6	£725	£4,325
	NHS North of Tyne	8	£970	£5,770
	NHS South of Tyne & Wear	6	£725	£4,325
	NHS Tees	5	£605	£3,605
	PbR excluded	NHS North East	25	£3,025
Further research or information	The group would welcome specific and explicit criteria that will identify patients with neovascular glaucoma for whom bevacizumab is likely to be the only remaining non-surgical treatment option.			